That being said, it is still unclear whether HNSCC patients will benefit from CDK 4/6 inhibitor monotherapy, but we anticipate that p16 loss and cyclin D1 amplification might serve as biomarkers for selecting patients for such treatment [43]. This evidence concerns the gene CDKN2A and head and neck squamous cell carcinoma.